IRWIS (IDegLira Real world Indian Study): A Real-World Observational Study For Use of IDegLira In Indian Patients

Abstract Introduction Novel therapies, like the fixed dose coformulation of insulin degludec (100 U/ml) and liraglutide (3.6 mg/ml) (IDegLira), are key to achieving glycemic targets in some patients with difficult to control diabetes. Our objective was to evaluate the efficacy and safety of IDegLira in Indian patients with type 2 diabetes mellitus that was inadequately controlled on multiple oral anti-diabetic agents with or without insulin therapy. Methods This was a multicenter, retrospective, real-world observational study. Clinical case records were analyzed for 61 patients with poorly controlled type 2 diabetes mellitus (HbA1c >8.5%) who were treated with IDegLira over a 26-week period. Results There were significant reductions in mean fasting (112.51± 24.80 vs. 188.48 ± 52.19 mg/dl; P Conclusions IDegLira had significant beneficial effects on glycaemic control and body weight over a 6-month period in Indian patients with type 2 diabetes that was poorly controlled on multiple oral anti-diabetic agents with or without insulin therapy. IDegLira was also found to be safe in this patient population.